prikaz prve stranice dokumenta A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment
  Download
PDF 595.35 KB
Scientific paper - Original scientific paper
A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment
Psychopharmacology, 233 (2016), 17; 3259-3267. https://doi.org/10.1007/s00213-016-4364-0
Šagud, Marina; Nikolac Perković, Matea; Vuksan-Ćusa, Bjanka; Maravić, Anja; Švob Štrac, Dubravka; Mihaljević Peleš, Alma; Živković, Maja; Kušević, Zorana; Pivac, Nela

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Šagud, M., Nikolac Perković, M., Vuksan Ćusa, B., Maravić, A., Švob Štrac, D., Mihaljević Peleš, A. ... Pivac, N. (2016). A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology, 233. (17), 3259-3267. doi: 10.1007/s00213-016-4364-0

Šagud, Marina, et al. "A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment." Psychopharmacology, vol. 233, no. 17, 2016, pp. 3259-3267. https://doi.org/10.1007/s00213-016-4364-0

Šagud, Marina, Matea Nikolac Perković, Bjanka Vuksan Ćusa, Anja Maravić, Dubravka Švob Štrac, Alma Mihaljević Peleš, Maja Živković, Zorana Kušević and Nela Pivac. "A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment." Psychopharmacology 233, no. 17 (2016): 3259-3267. https://doi.org/10.1007/s00213-016-4364-0

Šagud, M., et al. (2016) 'A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment', Psychopharmacology, 233(17), pp. 3259-3267. doi: 10.1007/s00213-016-4364-0

Šagud M, Nikolac Perković M, Vuksan Ćusa B, Maravić A, Švob Štrac D, Mihaljević Peleš A, and sur.. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology [Internet]. 2016 September [cited 2024 November 30];233(17):3259-3267. doi: 10.1007/s00213-016-4364-0

M. Šagud, et al., "A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment", Psychopharmacology, vol. 233, no. 17, pp. 3259-3267, September 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:274898. [Accessed: 30 November 2024]

Metadata
Title (english)A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment
AuthorMarina Šagud
AuthorMatea Nikolac Perković
AuthorBjanka Vuksan-Ćusa
AuthorAnja Maravić
AuthorDubravka Švob Štrac
AuthorAlma Mihaljević Peleš
AuthorMaja Živković
AuthorZorana Kušević
AuthorNela Pivac
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
BACKGROUND: Various antidepressants occupy brain serotonin transporter (SERT), decrease platelet serotonin (5-HT) concentration, and normalize reduced plasma brain-derived neurotrophic factor (BDNF) concentrations in depressed patients. Vortioxetine is a recently introduced antidepressant with a multimodal mechanism of action. In addition to SERT inhibition, vortioxetine acts via different 5-HT receptors. To further elucidate its mechanism of action, we have investigated the effects of vortioxetine on platelet 5-HT and plasma BDNF concentrations in patients with major depression. ----- METHODS: Platelet 5-HT and plasma BDNF concentrations were determined in 44 healthy subjects at baseline and in 44 depressed patients before and after 4 weeks of treatment with vortioxetine (5-15 mg daily). Platelet 5-HT concentration was determined using the ortho-phthalaldehyde-enhanced fluorometric method, and plasma BDNF concentration using a commercial enzyme-linked immunosorbent assay (Quantikine ELISA, R&D Systems). ----- RESULTS: At baseline, platelet 5-HT concentrations did not differ between depressed and control subjects, but plasma BDNF values were lower (p = 0.011; ω = 0.80) in depressed patients than in healthy subjects. Vortioxetine treatment significantly (p < 0.0001; ω = 0.80) decreased platelet 5-HT concentration and significantly (p = 0.004; ω = 0.80) increased plasma BDNF concentration in depressed patients compared to their baseline values. Age, gender, and smoking were not significantly associated with platelet 5-HT and plasma BDNF concentrations. ----- CONCLUSION: Despite a novel mechanism of action, vortioxetine shares some common effects with other antidepressants. This study is the first to show that, in addition to clinical improvement, 4 weeks of treatment with vortioxetine (5-15 mg daily), decreased platelet 5-HT and increased plasma BDNF concentrations in depressed patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titlePsychopharmacology
Numberingvol. 233, no. 17, pp. 3259-3267
p-ISSN0033-3158
DOIhttps://doi.org/10.1007/s00213-016-4364-0
URN:NBNurn:nbn:hr:105:274898
Publication2016-09
Document URLhttp://doi.org/10.1007/s00213-016-4364-0
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 09:01:10